Fenster schließen  |  Fenster drucken

[posting]37831899[/posting]Mela, vor der Zulassung, 98 % Erkennungsrate bei Hautkrebs, Wahnsinn!:eek:

A Big Upgrade for Electro-Optical Sciences
By Dave Mock
October 26, 2009 | Comments (0)


ShareThis MELA

Rate MELA CAPS Rating 5/5 Stars
$11.00 $0.80 (7.84%)

More about MELA
2 Stocks Hitting High Notes
Monday's Biggest Stock Stars
Disney Buys Marvel!David Gardner called it. He’s up 1,334%! See what David’s recommending that you buy NEXT.

Click Here Now

Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks-- and the track records of the companies behind them -- so individuals can make better investing decisions.

In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 140,000 members, many of whom demonstrate better investing insight than published analysts do.

After Electro-Optical Sciences (Nasdaq: MELA) spent the past several months at no better than a four-star ranking, enough top-performing CAPS members have become bullish on it recently to upgrade it to the highest possible five stars. A total of 139 members have given their opinion on the medical-devices company, with many of them offering analysis and commentary explaining the recent optimism.

Melanoma is the deadliest form of skin cancer and is often described as a graveyard for drugs because there are few treatments available. While Schering-Plough (NYSE: SGP) seeks approval for one of its drugs and Bristol-Myers Squibb (NYSE: BMY) has one in clinical trials, many others like Pfizer (NYSE: PFE) have failed in trying to market a treatment in the past. The Food and Drug Administration has put Electro-Optical Sciences' melanoma detection device, called MelaFind, on the fast track, with a decision coming as soon as the end of the year. Test results in February showed that MelaFind found 98% of the detectable melanomas in nearly 1,400 patients, while causing no adverse side effects. General Electric (NYSE: GE) and Siemens manufacture PET/CT scanners for early detection, but Electro-Optical's MelaFind is expected to play a big role in early detection if it is approved.

While other medical-devices companies such as Intuitive Surgical (Nasdaq: ISRG) and Boston Scientific (NYSE: BSX) have established histories and generate healthy revenue, Electro-Optical has no revenue or earnings yet and has relied on equity financing to get by. Some CAPS members write that the company is a speculative play, while some are drawn to MelaFind's potentially huge market and like the device's chances of winning approval
aus der Diskussion: Electro-Optical SCE kurz vor der Marktzulassung
Autor (Datum des Eintrages): Magnetfeldfredy  (26.10.09 20:55:38)
Beitrag: 4 von 4 (ID:38256666)
Alle Angaben ohne Gewähr © wallstreet:online